Compare Ally Financial Inc (ALLY) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Amgen, Inc. — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.32B), while Amgen, Inc. trades at $412.21 (market cap $225.71B). The key difference: Amgen, Inc. is far larger — about 16.9× Ally Financial Inc's market cap, and Ally Financial Inc pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| ALLY | AMGN | |
|---|---|---|
Market Cap | $13.32B | $225.71B |
Sector | Financials | Health |
52-Week High | $47.25 | $417.20 |
52-Week Low | $35.96 | $271.18 |
Dividend Yield | 2.74% | 2.42% |
Enterprise Value | — | $269.02B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
